Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs

@inproceedings{Tebbens2015ManagingTR,
  title={Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs},
  author={Radboud J Duintjer Tebbens and Kimberly M. Thompson},
  booktitle={BMC infectious diseases},
  year={2015}
}
BACKGROUND The Global Polio Eradication Initiative plans for coordinated cessation of oral poliovirus vaccine (OPV) use, beginning with serotype 2-containing OPV (i.e., OPV2 cessation) followed by the remaining two OPV serotypes (i.e., OPV13 cessation). The risk of circulating vaccine-derived poliovirus (cVDPV) outbreaks after OPV cessation of any serotype depends on the serotype-specific population immunity to transmission prior to its cessation. METHODS Based on an existing integrated… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS
14 Citations
33 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 33 references

The costs of polio risk management policies after eradication

  • RJ Duintjer Tebbens, N Sangrujee, KM. Thompson
  • Risk Anal. 2006;26(6):1507–31
  • 2015
Highly Influential
4 Excerpts

polio vaccine supply outlook - September 2014

  • UNICEF Ora
  • 2014. http:// www.unicef.org/supply/files…
  • 2015
1 Excerpt

Similar Papers

Loading similar papers…